Further references used to develop this protocol:
Phillips, K. A., R. L. Milne, M. A. Rookus, et al. 2013. "Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers." J Clin Oncol 31(25):3091-3099
Rebbeck, T. R., T. Friebel, H. T. Lynch, et al. 2004. "Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group." J Clin Oncol 22(6):1055-1062
Rebbeck, T. R., N. D. Kauff and S. M. Domchek. 2009. "Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers." J Natl Cancer Inst 101(2):80-87
Chen, S. and G. Parmigiani. 2007. "Meta-analysis of BRCA1 and BRCA2 penetrance." J Clin Oncol 25(11):1329-1333
Domchek, S. M., T. M. Friebel, C. F. Singer, et al. 2010. "Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality." JAMA 304(9):967-975
Kurian, A. W., B. M. Sigal and S. K. Plevritis. 2010. "Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers." J Clin Oncol 28(2):222-231
Rebbeck, T. R., T. Friebel, T. Wagner, et al. 2005. "Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group." J Clin Oncol 23(31):7804-7810
Antoniou, A., P. D. Pharoah, S. Narod, et al. 2003. "Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies." Am J Hum Genet 72(5):1117-1130.
Heemskerk-Gerritsen, B. A., M. B. Menke-Pluijmers, A. Jager, et al. 2013. "Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis." Ann Oncol 24(8):2029-2035.
Kriege, M., C. T. Brekelmans, C. Boetes, et al. 2006. "Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition." Cancer 106(11):2318-2326
Moorman, P. G., L. J. Havrilesky, J. M. Gierisch, et al. 2013. "Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis." J Clin Oncol 31(33):4188-4198.
Rijnsburger, A. J., I. M. Obdeijn, R. Kaas, et al. 2010. "BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study." J Clin Oncol 28(36):5265-5273.
Warner, E., K. Hill, P. Causer, et al. 2011. "Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging." J Clin Oncol 29(13):1664-1669
Woodward, E. R., H. V. Sleightholme, A. M. Considine, et al. 2007. "Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective." Bjog 114(12):1500-1509.
Tracey E, Kerr T, Dobrovic A, Currow D et al 2010 "Cancer in New South Wales: Incidence and Mortality Report 2008". Sydney: Cancer Institute NSW, August 2010